6
Diagnosis
Treatment
Adjuvant Therapy
Recommendation 4.1
➤ Patients with resected stage III NSCLC who did not receive
neoadjuvant systemic therapy should be offered adjuvant platinum-
based chemotherapy. (Strong recommendation; EB-B-H)
Recommendation 4.2
➤ Patients with resected stage III NSCLC with epidermal growth factor
receptor (EGFR) exon 19 deletion or exon 21 L858R mutation may
be offered adjuvant osimertinib after platinum-based chemotherapy.
(Strong recommendation; EB-B-M)
Recommendation 4.3
➤ For patients with completely resected NSCLC with mediastinal N2
involvement without extracapsular extension who have received
neoadjuvant or adjuvant platinum-based chemotherapy, postoperative
radiation therapy should not be routinely offered. (Weak
recommendation; EB-B/H-M)
Unresectable Disease
Recommendation 5.1
➤ Patients with stage III NSCLC who are medically or surgically
inoperable and good performance status should be offered concurrent
instead of sequential chemotherapy and radiation therapy. (Strong
recommendation; EB-B-H)
Recommendation 5.2
➤ Concurrent chemotherapy delivered with radiation therapy for
definitive treatment of stage III NSCLC should include a platinum-
based doublet, preferably cisplatin plus etoposide, carboplatin
plus paclitaxel, cisplatin plus pemetrexed (non-squamous only), or
cisplatin plus vinorelbine. (Strong recommendation; EB-B-H)
Qualifying statement: Carboplatin may be substituted for cisplatin in patients
with contraindications to or deemed ineligible for cisplatin.
